Searchable abstracts of presentations at key conferences in endocrinology

ea0031p158 | Neoplasia, cancer and late effects | SFEBES2013

Pituitary metasases: patients presenting with cranial nerve palsies and diabetes insipidus: a single centre experience

Salaris Paola , Kordbacheh Tiana , Whitelaw Ben , Mustafa Omar , Visca Anna , Thomas Nick , Bullock Peter , Barazi Sinan , Landau David , King Andrew , Hampton Timothy , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Pituitary metastases are a rare complication of systemic malignancy. The most common presentations of pituitary masses include visual field defects, headaches, and hypopituitarism, but cranial nerve palsies and diabetes insipidus are also recognised although unusual. We aimed to determine if these were more frequently associated with pituitary metastasis.Methods: We conducted a review of 944 patients undergoing pituitary surgery from a teachi...

ea0031p257 | Pituitary | SFEBES2013

Endocrine remission of Cushing's disease after endoscopic trans-sphenoidal surgery: Retrospective review of a single centre experience

Kennard Devon , Whitelaw Ben , Dworakowska Dorota , Thomas Nick , Barazi Sinan , Bullock Peter , King Andrew , Hampton Tim , Sherwood Roy , Buchanan Charles , Gilbert Jackie , McGregor Alan , Aylwin Simon

Background: Cushing’s disease is caused by corticotroph tumours of the pituitary gland and the standard first-line treatment is trans-sphenoidal surgery. Published data from other centres describes post-operative endocrine remission achieved in 50–90% of cases.Table 1 Remission (cortisol <50)Cortisol (50–150 nmol/l)<td alig...

ea0094p366 | Neuroendocrinology and Pituitary | SFEBES2023

MGMT and MSH2 immunohistochemistry status identifies a pituitary tumour subgroup with excellent progression free survival response to temozolomide: a single centre case series

Whitelaw Ben , Gilbert Jackie , Ling Chuah Ling , Crane James , Dimitriadis Georgios , Thomas Nick , Barazi Sinan , Maratos Eleni , Shapey Jonathan , Laniba Leah , Lazaro Nila , Gordon Nadia , Al-Salihi Omar , King Andrew , Al-Sarraj Safa , Reisz Zita , Bodi Istvan , Al Busaidi Ayisha , U-King-IM Jean-Marie , Aylwin Simon

Temozolomide has an established role as first line chemotherapy for aggressive pituitary adenoma and carcinoma. There are mixed reports whether the MGMT (methylguanine methyltransferase) and mismatch repair protein (MSH2/6) status of a tumour, assessed by immunohistochemistry (IHC) can predict response to temozolomide. This is the first series to assess combined MGMT and MSH2 status. We analysed a retrospective case series of patients treated with temozolomide at our tertiary ...